A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

FcRn: the neonatal Fc receptor comes of age

Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346 · see citing works

The Burden of Respiratory Syncytial Virus Infection in Young Children

Hall, C. B., Weinberg, G. A., Iwane, M. K., Blumkin, A. K., Edwards, K. M., Staat, M. A., Auinger, P., Griffin, M. R., Poehling, K. A., Erdman, D. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804877 · Cited by 2,250 · see citing works

Report of the Committee on Infectious Diseases

Nider, H. (1989) · Archives of Dermatology · doi:10.1001/archderm.1989.01670190156031 · Cited by 1,917 · see citing works

An Fc receptor structurally related to MHC class I antigens

Simister, N. E., & Mostov, K. E. (1989) · Nature · doi:10.1038/337184a0 · Cited by 729 · see citing works

Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)

Dall’Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 648 · see citing works

Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract

Wu, H., Pfarr, D. S., Johnson, S., Brewah, Y. A., Woods, R. M., Patel, N., White, W. I., Young, J. F., & Kiener, P. A. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.024 · Cited by 374 · see citing works

Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR

Suzuki, T., Ishii‐Watabe, A., Tada, M., Kobayashi, T., Kanayasu‐Toyoda, T., Kawanishi, T., & Yamaguchi, T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903296 · Cited by 368 · see citing works

Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences

Acqua, W. F. D., Woods, R. M., Ward, E. S., Palaszynski, S., Patel, N., Brewah, Y. A., Wu, H., Kiener, P. A., & Langermann, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.5171 · Cited by 368 · see citing works

Isolation and characterization of an Fc receptor from neonatal rat small intestine

Simister, N. E., & Rees, A. R. (1985) · European Journal of Immunology · doi:10.1002/eji.1830150718 · Cited by 341 · see citing works

Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates

Yeung, Y. A., Leabman, M. K., Marvin, J. S., Qiu, J., Adams, C. W., Lien, S., Starovasnik, M. A., & Lowman, H. B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804182 · Cited by 237 · see citing works

Neonatal Fc receptor and IgG-based therapeutics

Kuo, T. T., & Aveson, V. G. (2011) · mAbs · doi:10.4161/mabs.3.5.16983 · Cited by 236 · see citing works

The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development.

Mould, D. R., & Sweeney, K. (2007) · PubMed · Cited by 172 · see citing works

Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences

Wang, W., Lü, P., Fang, Y., Hamuro, L., Pittman, T. J., Carr, B. I., Hochman, J. H., & Prueksaritanont, T. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039453 · Cited by 166 · see citing works

Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay

Anderson, L. J., Hierholzer, J. C., Bingham, P. G., & Stone, Y. O. (1985) · Journal of Clinical Microbiology · doi:10.1128/jcm.22.6.1050-1052.1985 · Cited by 114 · see citing works

Serum IgG, IgM, and IgA levels in ankylosing spondylitis.

Veys, E. M., & van Leare, M. (1973) · Annals of the Rheumatic Diseases · doi:10.1136/ard.32.6.493 · Cited by 78 · see citing works

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Motavizumab, a Humanized, Enhanced-Potency Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus Infection in At-Risk Children

Abarca, K., V, Jung, E., Fernández, P., Zhao, L., Harris, B., Connor, E. M., & Losonsky, G. A. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31818ffd03 · Cited by 57 · see citing works

Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis

Groothuis, J. R., Hoopes, J. M., & Hemming, V. G. (2011) · Advances in Therapy · doi:10.1007/s12325-010-0101-y · Cited by 38 · see citing works

Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection

Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y., Murray, D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., et al. (2014) · PEDIATRICS · doi:10.1542/peds.2014-1665 · Cited by 769 · see citing works

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

Griffin, M. P., Yuan, Y., Takas, T., Domachowske, J. B., Madhi, S. A., Manzoni, P., Simões, E. A. F., Esser, M. T., Khan, A. A., Dubovsky, F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913556 · Cited by 778 · see citing works

Next generation antibody drugs: pursuit of the 'high-hanging fruit'

Carter, P. J., & Lazar, G. A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 760 · see citing works

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

Levin, M. J., Ustianowski, A., Wit, S. D., Launay, O., Avila, M., Templeton, A., Yuan, Y., Seegobin, S., Ellery, A., Levinson, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116620 · Cited by 691 · see citing works

Malaria

Phillips, M. A., Burrows, J. N., Manyando, C., van Huijsduijnen, R. H., A, W. C. V. V., & Wells, T. N. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.50 · Cited by 648 · see citing works

Antibody Structure and Function: The Basis for Engineering Therapeutics

Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 646 · see citing works

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

Mazur, N. I., Higgins, D., Nunes, M. C., Melero, J. A., Langedijk, A. C., Horsley, N., Buchholz, U. J., Openshaw, P., McLellan, J. S., Englund, J. A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30292-5 · Cited by 457 · see citing works

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins

Liming, L. (2017) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 394 · see citing works

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

Ko, S., Pegu, A., Rudicell, R. S., Yang, Z., Joyce, M. G., Chen, X., Wang, K., Bao, S., Kraemer, T. D., Räth, T., et al. (2014) · Nature · doi:10.1038/nature13612 · Cited by 374 · see citing works

Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection

Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y., Murray, D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., et al. (2014) · PEDIATRICS · doi:10.1542/peds.2014-1666 · Cited by 384 · see citing works

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants

Zhu, Q., McLellan, J. S., Kallewaard, N. L., Ulbrandt, N. D., Palaszynski, S., Zhang, J., Moldt, B., Khan, A. A., Svabek, C., McAuliffe, J. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj1928 · Cited by 363 · see citing works

IgG Fc engineering to modulate antibody effector functions

Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356 · see citing works

Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life

Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 315 · see citing works

Considerations for the Design of Antibody-Based Therapeutics

Goulet, D. R., & Atkins, W. M. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 305 · see citing works

Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development

Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299 · see citing works

Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics

Mazur, N. I., Martinón‐Torres, F., Baraldi, E., Fauroux, B., Greenough, A., Heikkinen, T., Manzoni, P., Mejías, A., Nair, H., Papadopoulos, N. G., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00255-6 · Cited by 297 · see citing works

The therapeutic age of the neonatal Fc receptor

Pyzik, M., Kozicky, L. K., Gandhi, A. K., & Blumberg, R. S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00821-1 · Cited by 288 · see citing works

Current progress in innovative engineered antibodies

Strohl, W. R. (2017) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 282 · see citing works

Monoclonal antibody therapies against SARS-CoV-2

Focosi, D., McConnell, S. A., Casadevall, A., Cappello, E., Valdiserra, G., & Tuccori, M. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00311-5 · Cited by 262 · see citing works

Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms

Oganesyan, V., Damschroder, M. M., Cook, K. E., Li, Q., Gao, C., Wu, H., & Dall'Acqua, W. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537563 · Cited by 259 · see citing works

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

Bar‐On, Y., Gruell, H., Schoofs, T., Pai, J. A., Nogueira, L., Butler, A. L., Millard, K. G., Lehmann, C., Suárez, I., Oliveira, T. Y., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0186-4 · Cited by 254 · see citing works

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

Gaudinski, M. R., Coates, E. E., Houser, K. V., Chen, G. L., Yamshchikov, G. V., Saunders, J. G., Holman, L. A., Gordon, I. J., Plummer, S. H., Hendel, C. S., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002493 · Cited by 241 · see citing works

Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection

Hwang, Y., Lu, R., Su, S.-C., Chiang, P.-Y., Ko, S.-H., Ke, F.-Y., Liang, K.-H., Hsieh, T.-Y., & Wu, H. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-021-00784-w · Cited by 236 · see citing works

The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy

Sockolosky, J. T., & Szoka, F. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.02.005 · Cited by 237 · see citing works

Aptamer Therapeutics in Cancer: Current and Future

Morita, Y., Leslie, M., Kameyama, H., Volk, D. E., & Tanaka, T. (2018) · Cancers · doi:10.3390/cancers10030080 · Cited by 219 · see citing works

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans

Loo, Y., McTamney, P. M., Arends, R. H., Gasser, R. A., Abram, M. E., Cheng, L., Diallo, S., Flores, D. J., Bond, N. J., Ren, K., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl8124 · Cited by 217 · see citing works

Half-life extended biotherapeutics

Kontermann, R. E. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1165661 · Cited by 193 · see citing works

Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial

O’Brien, K. L., Chandran, A., Weatherholtz, R., Jafri, H. S., Griffin, M. P., Bellamy, T., Millar, E. V., Jensen, K. M., Harris, B., Reid, R., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00247-9 · Cited by 190 · see citing works

Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?

Marshall, M. J. E., Stopforth, R. J., & Cragg, M. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01245 · Cited by 184 · see citing works

Antibody therapies for the prevention and treatment of viral infections

Salazar, G. T., Zhang, N., Fu, T., & An, Z. (2017) · npj Vaccines · doi:10.1038/s41541-017-0019-3 · Cited by 171 · see citing works

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection

Resch, B. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1337614 · Cited by 159 · see citing works

Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies

Kamath, A. V. (2016) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2016.09.004 · Cited by 158 · see citing works

Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy

Almagro, J. C., Daniels‐Wells, T. R., Pérez‐Tapia, S. M., & Penichet, M. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01751 · Cited by 158 · see citing works

A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies

Kumari, M., Lu, R., Li, M., Huang, J., Hsu, F., Ko, S.-H., Ke, F.-Y., Su, S.-C., Liang, K.-H., Yuan, J. P., et al. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00852-9 · Cited by 157 · see citing works

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults

Griffin, M. P., Khan, A. A., Esser, M. T., Jensen, K. M., Takas, T., Kankam, M. K., Villafana, T. L., & Dubovsky, F. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01714-16 · Cited by 148 · see citing works

Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults

Yu, X., Robbie, G. J., Wu, Y., Esser, M. T., Jensen, K. M., Schwartz, H. I., Bellamy, T., Hernandez‐Illas, M., & Jafri, H. S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01020-16 · Cited by 140 · see citing works

Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement

Abu-Raya, B., Maertens, K., Edwards, K. M., Omer, S. B., Englund, J. A., Flanagan, K. L., Snape, M. D., Amirthalingam, G., Leuridan, E. E., Damme, P. V., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01282 · Cited by 134 · see citing works

Impact of structural modifications of IgG antibodies on effector functions

Damelang, T., Brinkhaus, M., van Osch, T. L. J., Schuurman, J., Labrijn, A. F., Rispens, T., & Vidarsson, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1304365 · Cited by 128 · see citing works

malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication

Elimination, T. M. R. C. P. O. T. F. M. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002455 · Cited by 119 · see citing works

Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions

Abdeldaim, D. T., & Schindowski, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102402 · Cited by 114 · see citing works

Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies

Avery, L. B., Wang, M., Kavosi, M. S., Joyce, A. P., Kurz, J. C., Fan, Y., Dowty, M. E., Zhang, M., Zhang, Y., Cheng, A., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1193660 · Cited by 110 · see citing works

Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides

Datta‐Mannan, A. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.086488 · Cited by 110 · see citing works

Targeting FcRn to Generate Antibody-Based Therapeutics

Ward, E. S., & Ober, R. J. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.07.007 · Cited by 109 · see citing works

Extending human IgG half-life using structure-guided design

Booth, B. J., Ramakrishnan, B., Narayan, K. M., Wollacott, A. M., Babcock, G. J., Shriver, Z. H., & Viswanathan, K. (2018) · mAbs · doi:10.1080/19420862.2018.1490119 · Cited by 111 · see citing works

Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases

Fukuzawa, T., Sampei, Z., Haraya, K., Ruike, Y., Shida-Kawazoe, M., Shimizu, Y., Gan, S. W., Irie, M., Tsuboi, Y., Tai, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01087-7 · Cited by 107 · see citing works

pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling

Borrok, M. J., Wu, Y., Beyaz, N., Yu, X., Oganesyan, V., Dall’Acqua, W. F., & Tsui, P. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.603712 · Cited by 107 · see citing works

Monoclonal Antibodies: Past, Present and Future

Posner, J., Barrington, P. J., Brier, T., & Datta‐Mannan, A. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_323 · Cited by 111 · see citing works

Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation

Igawa, T., Haraya, K., & Hattori, K. (2016) · Immunological Reviews · doi:10.1111/imr.12392 · Cited by 99 · see citing works

Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19

Sempowski, G. D., Saunders, K. O., Acharya, P., Wiehe, K. J., & Haynes, B. F. (2020) · Cell · doi:10.1016/j.cell.2020.05.041 · Cited by 100 · see citing works

A human endothelial cell-based recycling assay for screening of FcRn targeted molecules

Grevys, A., Nilsen, J., Sand, K. M. K., Daba, M. B., Øynebråten, I., Bern, M., McAdam, M. B., Foss, S., Schlothauer, T., Michaelsen, T. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03061-x · Cited by 98 · see citing works

Antibacterial monoclonal antibodies: the next generation?

DiGiandomenico, A., & Sellman, B. R. (2015) · Current Opinion in Microbiology · doi:10.1016/j.mib.2015.07.014 · Cited by 93 · see citing works

Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques

Magnani, D. M., Rogers, T. F., Beutler, N., Ricciardi, M. J., Bailey, V. K., Gonzalez-Nieto, L., Briney, B. S., Sok, D., Le, K. M., Strubel, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8184 · Cited by 93 · see citing works

Fifty years of monoclonals: the past, present and future of antibody therapeutics

Chan, A. C., Martyn, G. D., & Carter, P. J. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01207-9 · Cited by 96 · see citing works

Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy

Ghemrawi, R., Abuamer, L., Kremesh, S., Hussien, G., Ahmed, R., Mousa, W. K., Khoder, G., & Khair, M. (2024) · Biomedicines · doi:10.3390/biomedicines12092158 · Cited by 92 · see citing works

Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies

Glassman, P. M., & Balthasar, J. P. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9482-0 · Cited by 88 · see citing works

An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence

Lee, C., Kang, T. H., Godon, O., Watanabe, M., Delidakis, G., Gillis, C. M., Sterlin, D., Hardy, D., Cogné, M., Macdonald, L. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13108-2 · Cited by 87 · see citing works

Targeting FcRn for the modulation of antibody dynamics

Ward, E. S., Devanaboyina, S. C., & Ober, R. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.02.007 · Cited by 87 · see citing works

A molecular understanding of alphavirus entry and antibody protection

Kim, A. S., & Diamond, M. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00825-7 · Cited by 83 · see citing works

Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria

Foss, S., Sakya, S. A., Aguinagalde, L., Lustig, M., Shaughnessy, J., Cruz, A. R., Scheepmaker, L. M., Mathiesen, L., Ruso‐Julve, F., Anthi, A. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46321-9 · Cited by 85 · see citing works

Monoclonal antibodies: technologies for early discovery and engineering

Kennedy, P. J., Oliveíra, C., Granja, P. L., & Sarmento, B. F. C. C. (2017) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2017.1357002 · Cited by 85 · see citing works

Mechanisms of Neutralization of a Human Anti-α-toxin Antibody

Oganesyan, V., Peng, L., Damschroder, M. M., Li, C., Sadowska, A., Tkaczyk, C., Sellman, B. R., Wu, H., & Dall’Acqua, W. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.601328 · Cited by 84 · see citing works

Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis

Edavettal, S. C., Cejudo–Martín, P., Dasgupta, B., Yang, D., Buschman, M. D., Domingo, D. L., Kolen, K. V., Jaiprasart, P., Gordon, R. E., Schutsky, K., et al. (2022) · Med · doi:10.1016/j.medj.2022.09.007 · Cited by 83 · see citing works

Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies

Bas, M., Terrier, A., Jacque, E., Dehenne, A., Pochet-Béghin, V., Beghin, C., Dezetter, A.-S., Dupont, G., Engrand, A., Beaufils, B., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800896 · Cited by 82 · see citing works

Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation

Nixon, J. V., Newbold, P., Mustelin, T., Anderson, G. P., & Kolbeck, R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.016 · Cited by 82 · see citing works

Smart drug delivery of p-Coumaric acid loaded aptamer conjugated starch nanoparticles for effective triple-negative breast cancer therapy

Mariadoss, A. V. A., Saravanakumar, K., Sathiyaseelan, A., Karthikkumar, V., & Wang, M. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.11.170 · Cited by 79 · see citing works

Therapeutic monoclonal antibodies in allergy: Targeting IgE , cytokine, and alarmin pathways

Eggel, A., Pennington, L. F., & Jardetzky, T. S. (2024) · Immunological Reviews · doi:10.1111/imr.13380 · Cited by 76 · see citing works

Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life

Majumdar, R., Esfandiary, R., Bishop, S. M., Samra, H. S., Middaugh, C. R., Volkin, D. B., & Weis, D. D. (2014) · mAbs · doi:10.4161/19420862.2014.985494 · Cited by 75 · see citing works

Coming together at the hinges: Therapeutic prospects of IgG3

Chu, T. H., Patz, E. F., & Ackerman, M. E. (2021) · mAbs · doi:10.1080/19420862.2021.1882028 · Cited by 75 · see citing works

MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model

Hua, L., Cohen, T. S., Shi, Y., Datta, V., Hilliard, J. J., Tkaczyk, C., Suzich, J., Stover, C. K., & Sellman, B. R. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00510-15 · Cited by 74 · see citing works

Harnessing Fc receptor biology in the design of therapeutic antibodies

Sondermann, P., & Szymkowski, D. E. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.005 · Cited by 70 · see citing works

Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins

Quiroz, J. A., Malonis, R. J., Thackray, L. B., Cohen, C. A., Pallesen, J., Jangra, R. K., Brown, R. S., Hofmann, D., Holtsberg, F. W., Shulenin, S., et al. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1008061 · Cited by 67 · see citing works

A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates

Keeffe, J. R., Rompay, K. K. A. V., Olsen, P. C., Wang, Q., Gazumyan, A., Azzopardi, S. A., Schaefer-Babajew, D. J., Lee, Y. E., Stuart, J. B., Singapuri, A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.031 · Cited by 68 · see citing works

A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults

Aliprantis, A. O., Wolford, D. G., Caro, L., Maas, B. M., Ma, H., Montgomery, D. L., Sterling, L. M., Hunt, A., Cox, K. S., Vora, K. A., et al. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.883 · Cited by 67 · see citing works

Influence of Charge, Hydrophobicity, and Size on Vitreous Pharmacokinetics of Large Molecules

Crowell, S. R., Wang, K., Famili, A., Shatz-Binder, W., Loyet, K. M., Chang, V., Liu, Y., Prabhu, S., Kamath, A. V., & Kelley, R. F. (2019) · Translational Vision Science & Technology · doi:10.1167/tvst.8.6.1 · Cited by 62 · see citing works

A cocktail of humanized anti–pertussis toxin antibodies limits disease in murine and baboon models of whooping cough

Nguyen, A. W., Wagner, E. K., Laber, J. R., Goodfield, L. L., Smallridge, W. E., Harvill, E. T., Papin, J. F., Wolf, R. F., PADLAN, E. A., Bristol, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad0966 · Cited by 61 · see citing works

Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials

Broadbent, L., Groves, H. E., Shields, M. D., & Power, U. F. (2015) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12313 · Cited by 60 · see citing works

Tixagevimab + Cilgavimab: First Approval

Keam, S. J. (2022) · Drugs · doi:10.1007/s40265-022-01731-1 · Cited by 60 · see citing works

Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®

Magnenat, L., Palmese, A., Frémaux, C., D'Amici, F., Terlizzese, M., Rossi, M., & Chevalet, L. (2016) · mAbs · doi:10.1080/19420862.2016.1259046 · Cited by 59 · see citing works

Optimization of therapeutic antibodies

Wang, B., Kankanamalage, S. G., Dong, J., & Liu, Y. (2021) · Antibody Therapeutics · doi:10.1093/abt/tbab003 · Cited by 58 · see citing works

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment

Focosi, D., & Casadevall, A. (2022) · Viruses · doi:10.3390/v14091999 · Cited by 59 · see citing works

Anti-Alpha-Toxin Monoclonal Antibody and Antibiotic Combination Therapy Improves Disease Outcome and Accelerates Healing in a Staphylococcus aureus Dermonecrosis Model

Hilliard, J., Datta, V., Tkaczyk, C., Hamilton, M., Sadowska, A., Jones-Nelson, O., O'Day, T., Weiss, W. J., Szarka, S., Nguyen, V., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03918-14 · Cited by 56 · see citing works

Viral infection neutralization tests: A focus on severe acute respiratory syndrome‐coronavirus‐2 with implications for convalescent plasma therapy

Focosi, D., Maggi, F., Mazzetti, P., & Pistello, M. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2170 · Cited by 57 · see citing works

The Highly Evolvable Antibody Fc Domain

Park, H. I., Yoon, H. W., & Jung, S. T. (2016) · Trends in biotechnology · doi:10.1016/j.tibtech.2016.04.005 · Cited by 54 · see citing works

Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection

Mejías, A., García-Mauriño, C., Fernández, R. R., Peeples, M. E., & Ramilo, O. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.09.026 · Cited by 54 · see citing works

Passive and active immunization against respiratory syncytial virus for the young and old

Villafana, T. L., Falloon, J., Griffin, M. P., Zhu, Q., & Esser, M. T. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1333425 · Cited by 53 · see citing works

In Translation: FcRn across the Therapeutic Spectrum

Qi, T., & Cao, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063048 · Cited by 53 · see citing works

Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging

Vivier, D., Sharma, S. K., & Zeglis, B. M. (2018) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3628 · Cited by 53 · see citing works

Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies

Leipold, D. D., & Prabhu, S. (2018) · Clinical and Translational Science · doi:10.1111/cts.12597 · Cited by 54 · see citing works

Prevention of Pediatric Respiratory Syncytial Virus Lower Respiratory Tract Illness: Perspectives for the Next Decade

Aranda, S. S., & Polack, F. P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01006 · Cited by 54 · see citing works

Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRnin vitroandin vivo

Mester, S., Evers, M., Meyer, S., Nilsen, J., Greiff, V., Sandlie, I., Leusen, J. H. W., & Andersen, J. T. (2021) · mAbs · doi:10.1080/19420862.2021.1893888 · Cited by 52 · see citing works

Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Infection

Fernández, R. R., Mejías, A., & Ramilo, O. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003121 · Cited by 52 · see citing works

Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions

Monnet, C., Jorieux, S., Urbain, R., Fournier, N., Bouayadi, K., de Romeuf, C., Behrens, C. K., Fontayne, A., & Mondon, P. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00039 · Cited by 52 · see citing works

An “Fc-Silenced” IgG1 Format With Extended Half-Life Designed for Improved Stability

Borrok, M. J., Mody, N., Lu, X., Kuhn, M. L., Wu, H., Dall’Acqua, W. F., & Tsui, P. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.12.023 · Cited by 52 · see citing works

Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life

Grevys, A., Frick, R., Mester, S., Flem-Karlsen, K., Nilsen, J., Foss, S., Sand, K. M. K., Emrich, T., Fischer, J. A. A., Greiff, V., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103746 · Cited by 51 · see citing works

A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state

Teranishi-Ikawa, Y., Soeda, T., Koga, H., Yamaguchi, K., Kato, K., Esaki, K., Asanuma, K., Funaki, M., Ichiki, M., Ikuta, Y., et al. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.09.034 · Cited by 51 · see citing works

Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody

Monnet, C., Jorieux, S., Souyris, N., Zaki, O., Jacquet, A., Fournier, N., Crozet, F., de Romeuf, C., Bouayadi, K., Urbain, R., et al. (2014) · mAbs · doi:10.4161/mabs.27854 · Cited by 51 · see citing works

Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults

Phuah, J. Y., Maas, B. M., Tang, A., Zhang, Y., Caro, L., Railkar, R. A., Swanson, M. D., Cao, Y., Li, H., Roadcap, B. A., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115851 · Cited by 50 · see citing works

Neutralization of pertussis toxin by a single antibody prevents clinical pertussis in neonatal baboons

Nguyen, A. W., DiVenere, A. M., Papin, J. F., Connelly, S., Kaleko, M., & Maynard, J. A. (2020) · Science Advances · doi:10.1126/sciadv.aay9258 · Cited by 50 · see citing works

Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention

Kisalu, N. K., Pereira, L. D. S., Ernste, K., Flores-García, Y., Idris, A. H., Asokan, M., Dillon, M., MacDonald, S. W., Shi, W., Chen, X., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.143958 · Cited by 48 · see citing works

Broadly neutralizing antibodies in HIV-1 treatment and prevention

Kumar, R., Qureshi, H., Deshpande, S., & Bhattacharya, J. (2018) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/2515135518800689 · Cited by 46 · see citing works

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Motavizumab, a Humanized, Enhanced-Potency Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus Infection in At-Risk Children

Abarca, K., V, Jung, E., Fernández, P., Zhao, L., Harris, B., Connor, E. M., & Losonsky, G. A. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31818ffd03 · Cited by 57 · see citing works

YTE-engineered antibodies: From neonatal Fc receptor binding mechanisms to next-generation therapeutics

Dubey, S. D. (2026) · International Journal of Molecular and Immuno Oncology · doi:10.25259/ijmio_32_2025 · Cited by 1 · see citing works

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults

Griffin, M. P., Khan, A. A., Esser, M. T., Jensen, K. M., Takas, T., Kankam, M. K., Villafana, T. L., & Dubovsky, F. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01714-16 · Cited by 148 · see citing works

SAFETY AND ANTIVIRAL ACTIVITY OF MOTAVIZUMAB, A RESPIRATORY SYNCYTIAL VIRUS (RSV)–SPECIFIC HUMANIZED MONOCLONAL ANTIBODY, WHEN ADMINISTERED TO RSV-INFECTED CHILDREN

Lagos, R., DeVincenzo, J. P., Muñoz, A., Hultquist, M., Suzich, J., Connor, E. M., & Losonsky, G. A. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181a165e4 · Cited by 55 · see citing works

Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants

Domachowske, J. B., Khan, A. A., Esser, M. T., Jensen, K. M., Takas, T., Villafana, T. L., Dubovsky, F., & Griffin, M. P. (2018) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001916 · Cited by 230 · see citing works